370 related articles for article (PubMed ID: 10853980)
1. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
Dupont C; Vasseur E; Beauchet A; Aegerter P; Berthé H; de Truchis P; Zucman D; Rouveix E; Saiag P
AIDS; 2000 May; 14(8):987-93. PubMed ID: 10853980
[TBL] [Abstract][Full Text] [Related]
2. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy.
Cattelan AM; Calabrò ML; De Rossi A; Aversa SM; Barbierato M; Trevenzoli M; Gasperini P; Zanchetta M; Cadrobbi P; Monfardini S; Chieco-Bianchi L
Int J Oncol; 2005 Sep; 27(3):779-85. PubMed ID: 16077928
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
[TBL] [Abstract][Full Text] [Related]
4. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
[TBL] [Abstract][Full Text] [Related]
5. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
[TBL] [Abstract][Full Text] [Related]
6. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma.
Bower M; Fox P; Fife K; Gill J; Nelson M; Gazzard B
AIDS; 1999 Oct; 13(15):2105-11. PubMed ID: 10546864
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
Lebbé C; Blum L; Pellet C; Blanchard G; Vérola O; Morel P; Danne O; Calvo F
AIDS; 1998 May; 12(7):F45-9. PubMed ID: 9619797
[TBL] [Abstract][Full Text] [Related]
8. Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor.
Murdaca G; Campelli A; Setti M; Indiveri F; Puppo F
AIDS; 2002 Jan; 16(2):304-5. PubMed ID: 11807324
[No Abstract] [Full Text] [Related]
9. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.
Martinez V; Caumes E; Gambotti L; Ittah H; Morini JP; Deleuze J; Gorin I; Katlama C; Bricaire F; Dupin N
Br J Cancer; 2006 Apr; 94(7):1000-6. PubMed ID: 16570046
[TBL] [Abstract][Full Text] [Related]
10. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy.
Núñez M; Saballs P; Valencia ME; Santos J; Ferrer E; Santos I; Berrocal A; Galindo MJ; Podzamczer D; Gonzlez-Lahoz J;
HIV Clin Trials; 2001; 2(5):429-37. PubMed ID: 11673818
[TBL] [Abstract][Full Text] [Related]
11. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma.
Dupin N; Rubin De Cervens V; Gorin I; Calvez V; Pessis E; Grandadam M; Rabian C; Viard JP; Huraux JM; Escande JP
Br J Dermatol; 1999 May; 140(5):875-81. PubMed ID: 10354025
[TBL] [Abstract][Full Text] [Related]
12. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
[TBL] [Abstract][Full Text] [Related]
13. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.
Nasti G; Talamini R; Antinori A; Martellotta F; Jacchetti G; Chiodo F; Ballardini G; Stoppini L; Di Perri G; Mena M; Tavio M; Vaccher E; D'Arminio Monforte A; Tirelli U;
J Clin Oncol; 2003 Aug; 21(15):2876-82. PubMed ID: 12885804
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for Kaposi's sarcoma in human immunodeficiency virus patients after initiation of antiretroviral therapy: A nested case-control study in Kenya.
Lupia R; Wabuyia PB; Otiato P; Fang CT; Tsai FJ
J Microbiol Immunol Infect; 2017 Dec; 50(6):781-788. PubMed ID: 26712092
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.
Uldrick TS; Wyvill KM; Kumar P; O'Mahony D; Bernstein W; Aleman K; Polizzotto MN; Steinberg SM; Pittaluga S; Marshall V; Whitby D; Little RF; Yarchoan R
J Clin Oncol; 2012 May; 30(13):1476-83. PubMed ID: 22430271
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma.
Gill J; Bourboulia D; Wilkinson J; Hayes P; Cope A; Marcelin AG; Calvez V; Gotch F; Boshoff C; Gazzard B
J Acquir Immune Defic Syndr; 2002 Dec; 31(4):384-90. PubMed ID: 12447008
[TBL] [Abstract][Full Text] [Related]
17. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma.
Tam HK; Zhang ZF; Jacobson LP; Margolick JB; Chmiel JS; Rinaldo C; Detels R
Int J Cancer; 2002 Apr; 98(6):916-22. PubMed ID: 11948473
[TBL] [Abstract][Full Text] [Related]
18. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.
Portsmouth S; Stebbing J; Gill J; Mandalia S; Bower M; Nelson M; Bower M; Gazzard B
AIDS; 2003 Jul; 17(11):F17-22. PubMed ID: 12853764
[TBL] [Abstract][Full Text] [Related]
19. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome.
Cattelan AM; Calabro ML; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
Eur J Cancer; 1999 Dec; 35(13):1809-15. PubMed ID: 10673996
[TBL] [Abstract][Full Text] [Related]
20. [Kaposi sarcoma in HIV patients: Response to antiretroviral treatment and chemotherapy].
Lasso M; Pérez J; Noriega L; Malebrán A; Espinoza S
Rev Med Chil; 2003 May; 131(5):483-90. PubMed ID: 12879808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
